^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Sulanda (surufatinib)

    i
    Other names: HMPL-012, HMPL012, HMPL 012
    Company:
    Hutchmed
    Drug class:
    VEGFR-2 inhibitor, VEGFR inhibitor, CSF-1R inhibitor, FGFR1 inhibitor, VEGFR-1 inhibitor, VEGFR-3 inhibitor
    Related drugs:
    1m
    Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2, N=160, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Sulanda (surufatinib)
    2ms
    HMPL-012-SPRING-P105: Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital | Trial completion date: May 2026 --> Dec 2026
    Trial completion date
    |
    gemcitabine • albumin-bound paclitaxel • Sulanda (surufatinib)
    2ms
    HMPL-012-SPRING-OS101: Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=47, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Sulanda (surufatinib)
    2ms
    HMPL-012-SPRING-NEN109: A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors (clinicaltrials.gov)
    P2, N=6, Terminated, Changhai Hospital | N=100 --> 6 | Trial completion date: Nov 2026 --> Jun 2026 | Not yet recruiting --> Terminated | Trial primary completion date: Nov 2026 --> Jun 2026; This investigator-initiated study closed to recruitment early due to slower-than-anticipated patient accrual.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Sulanda (surufatinib)
    2ms
    Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    cisplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • Sulanda (surufatinib)
    3ms
    Targeting GPR34 in damage-associated macrophages enhances anti-tumor immunity and the efficacy of Surufatinib in pancreatic cancer. (PubMed, Signal Transduct Target Ther)
    Combining a GPR34 antagonist with chemotherapy and surufatinib significantly enhanced anti-tumor responses in preclinical models. These findings identify GPR34 as a promising immune therapeutic target.
    Journal
    |
    CD8 (cluster of differentiation 8) • CSF1R (Colony stimulating factor 1 receptor)
    |
    Sulanda (surufatinib)
    4ms
    Efficacy and Safety of Surufatinib in Treating Pituitary Neuroendocrine Tumors: A Single-Center, Single-Arm, Exploratory Study (ChiCTR2600120740)
    P=N/A, N=40, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University
    New trial
    |
    Sulanda (surufatinib)
    4ms
    Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study (clinicaltrials.gov)
    P=N/A, N=500, Active, not recruiting, West China Hospital
    New trial
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    Sulanda (surufatinib)
    4ms
    STARS-RC10: Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria (clinicaltrials.gov)
    P2/3, N=212, Recruiting, The First Hospital of Jilin University
    New P2/3 trial
    |
    Loqtorzi (toripalimab-tpzi) • capecitabine • oxaliplatin • Sulanda (surufatinib)
    5ms
    Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • oxaliplatin • irinotecan • Sulanda (surufatinib)
    5ms
    Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=29, Completed, Sun Yat-sen University | Recruiting --> Completed | Trial completion date: Aug 2025 --> Jan 2026
    Trial completion • Trial completion date • Platinum resistant
    |
    Partruvix (pamiparib) • Sulanda (surufatinib)
    5ms
    Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)
    P3, N=106, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P3 trial
    |
    gemcitabine • capecitabine • albumin-bound paclitaxel • Sulanda (surufatinib)